Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
LJ Holmes (Manchester, United Kingdom), L.J. Holmes, D. Ryan, G.A. Tavernier, R.M. Niven. A clinically observed variability in serum total IgE in patients being considered for omalizumab therapy. Eur Respir J 2016; 48: Suppl. 60, 4101

Member's Comments

No comment yet.

Related content which might interest you: Total and free IgE in evolution of severe asthma after omalizumab treatment Source: International Congress 2016 – Asthma management Year: 2016 Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015 Free serum IL-18 levels and responsiveness to omalizumab in patients with severe asthma Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding Year: 2016 Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 Variability of total serum IgE in moderate-to-severe asthmatic patients Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Obese patients with partially controlled asthma: Weight control shows more benefit in IgE low patients Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding Year: 2016 Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma Source: Annual Congress 2013 –Studies of asthma in man Year: 2013 Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Omalizumab add-on therapy reduces exacerbations among responders: A pooled NNT analysis from 5 phase 3 studies Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007 Laser acupuncture effects on serum immunoglobulin E in A topic bronchial asthma patients Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 Blood eosinophil dose response to oral corticosteroids in a population of patients with severe asthma Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007 Monitoring free serum IgE in severe asthma patients treated with omalizumab Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Monitoring free serum IgE in asthma patients treated with omalizumab Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 Can blood investigations be utilised to predict treatment response to omalizumab? Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 Asthma control is reached in a large majority of asthmatics treated with omalizumab. An Italian observational study Source: Annual Congress 2013 –Disease control and quality of life in airway diseases Year: 2013